Nicotine-haloperidol interactions and cognitive performance in schizophrenics

Edward D. Levin, William Wilson, Jed E. Rose, Joseph Patrick McEvoy

Research output: Contribution to journalArticle

311 Citations (Scopus)

Abstract

Nearly 90% of schizophrenics smoke cigarettes, considerably higher than the general population's rate of 25%. There is some indication that schizophrenics may smoke as a form of self-medication. Nicotine has a variety of pharmacologic effects that may both counteract some of the cognitive deficits of schizophrenia and counteract some of the adverse side effects of antipsychotic drugs. In the current study, we assessed the interactions of haloperidol and nicotine on cognitive performance of a group of schizophrenics. These patients were in a double-blind study, randomly assigning them to low, moderate, and high dose levels of haloperidol. The subjects, all smokers, came to the laboratory on four different mornings after overnight deprivation from cigarettes. In a double-blind fashion, they were administered placebo, low (7 mg/day), medium (14 mg/day), or high (21 mg/day), medium (14 mg/day), or high (21 mg/day) dose nicotine skin patches. Three hours after administration of the skin patch, the subjects were given a computerized cognitive test battery including: simple reaction time, complex reaction time (spatial rotation), delayed matching to sample, the Sternberg memory test, and the Conners continuous performance test (CPT). With the placebo nicotine patch, there was a haloperidol dose-related impairment in delayed matching to sample choice accuracy and an increase in response time on the complex reaction time task. Nicotine caused a dose-related reversal of the haloperidol-induced impairments in memory performance and complex reaction time. In the CPT, nicotine reduced the variability in response that is associated with attentional deficit. These results demonstrate the effects of nicotine in reversing some of the adverse side effects of haloperidol and improving cognitive performance in schizophrenia.

Original languageEnglish (US)
Pages (from-to)429-436
Number of pages8
JournalNeuropsychopharmacology
Volume15
Issue number5
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Haloperidol
Nicotine
Reaction Time
Tobacco Use Cessation Products
Smoke
Tobacco Products
Schizophrenia
Placebos
Self Medication
Skin
Drug-Related Side Effects and Adverse Reactions
Double-Blind Method
Antipsychotic Agents
Population

Keywords

  • Haloperidol
  • Memory
  • Nicotine
  • Reaction time
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Nicotine-haloperidol interactions and cognitive performance in schizophrenics. / Levin, Edward D.; Wilson, William; Rose, Jed E.; McEvoy, Joseph Patrick.

In: Neuropsychopharmacology, Vol. 15, No. 5, 01.01.1996, p. 429-436.

Research output: Contribution to journalArticle

Levin, Edward D. ; Wilson, William ; Rose, Jed E. ; McEvoy, Joseph Patrick. / Nicotine-haloperidol interactions and cognitive performance in schizophrenics. In: Neuropsychopharmacology. 1996 ; Vol. 15, No. 5. pp. 429-436.
@article{eb2a04fae0674e8ebc7af4e833aa2568,
title = "Nicotine-haloperidol interactions and cognitive performance in schizophrenics",
abstract = "Nearly 90{\%} of schizophrenics smoke cigarettes, considerably higher than the general population's rate of 25{\%}. There is some indication that schizophrenics may smoke as a form of self-medication. Nicotine has a variety of pharmacologic effects that may both counteract some of the cognitive deficits of schizophrenia and counteract some of the adverse side effects of antipsychotic drugs. In the current study, we assessed the interactions of haloperidol and nicotine on cognitive performance of a group of schizophrenics. These patients were in a double-blind study, randomly assigning them to low, moderate, and high dose levels of haloperidol. The subjects, all smokers, came to the laboratory on four different mornings after overnight deprivation from cigarettes. In a double-blind fashion, they were administered placebo, low (7 mg/day), medium (14 mg/day), or high (21 mg/day), medium (14 mg/day), or high (21 mg/day) dose nicotine skin patches. Three hours after administration of the skin patch, the subjects were given a computerized cognitive test battery including: simple reaction time, complex reaction time (spatial rotation), delayed matching to sample, the Sternberg memory test, and the Conners continuous performance test (CPT). With the placebo nicotine patch, there was a haloperidol dose-related impairment in delayed matching to sample choice accuracy and an increase in response time on the complex reaction time task. Nicotine caused a dose-related reversal of the haloperidol-induced impairments in memory performance and complex reaction time. In the CPT, nicotine reduced the variability in response that is associated with attentional deficit. These results demonstrate the effects of nicotine in reversing some of the adverse side effects of haloperidol and improving cognitive performance in schizophrenia.",
keywords = "Haloperidol, Memory, Nicotine, Reaction time, Schizophrenia",
author = "Levin, {Edward D.} and William Wilson and Rose, {Jed E.} and McEvoy, {Joseph Patrick}",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/S0893-133X(96)00018-8",
language = "English (US)",
volume = "15",
pages = "429--436",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Nicotine-haloperidol interactions and cognitive performance in schizophrenics

AU - Levin, Edward D.

AU - Wilson, William

AU - Rose, Jed E.

AU - McEvoy, Joseph Patrick

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Nearly 90% of schizophrenics smoke cigarettes, considerably higher than the general population's rate of 25%. There is some indication that schizophrenics may smoke as a form of self-medication. Nicotine has a variety of pharmacologic effects that may both counteract some of the cognitive deficits of schizophrenia and counteract some of the adverse side effects of antipsychotic drugs. In the current study, we assessed the interactions of haloperidol and nicotine on cognitive performance of a group of schizophrenics. These patients were in a double-blind study, randomly assigning them to low, moderate, and high dose levels of haloperidol. The subjects, all smokers, came to the laboratory on four different mornings after overnight deprivation from cigarettes. In a double-blind fashion, they were administered placebo, low (7 mg/day), medium (14 mg/day), or high (21 mg/day), medium (14 mg/day), or high (21 mg/day) dose nicotine skin patches. Three hours after administration of the skin patch, the subjects were given a computerized cognitive test battery including: simple reaction time, complex reaction time (spatial rotation), delayed matching to sample, the Sternberg memory test, and the Conners continuous performance test (CPT). With the placebo nicotine patch, there was a haloperidol dose-related impairment in delayed matching to sample choice accuracy and an increase in response time on the complex reaction time task. Nicotine caused a dose-related reversal of the haloperidol-induced impairments in memory performance and complex reaction time. In the CPT, nicotine reduced the variability in response that is associated with attentional deficit. These results demonstrate the effects of nicotine in reversing some of the adverse side effects of haloperidol and improving cognitive performance in schizophrenia.

AB - Nearly 90% of schizophrenics smoke cigarettes, considerably higher than the general population's rate of 25%. There is some indication that schizophrenics may smoke as a form of self-medication. Nicotine has a variety of pharmacologic effects that may both counteract some of the cognitive deficits of schizophrenia and counteract some of the adverse side effects of antipsychotic drugs. In the current study, we assessed the interactions of haloperidol and nicotine on cognitive performance of a group of schizophrenics. These patients were in a double-blind study, randomly assigning them to low, moderate, and high dose levels of haloperidol. The subjects, all smokers, came to the laboratory on four different mornings after overnight deprivation from cigarettes. In a double-blind fashion, they were administered placebo, low (7 mg/day), medium (14 mg/day), or high (21 mg/day), medium (14 mg/day), or high (21 mg/day) dose nicotine skin patches. Three hours after administration of the skin patch, the subjects were given a computerized cognitive test battery including: simple reaction time, complex reaction time (spatial rotation), delayed matching to sample, the Sternberg memory test, and the Conners continuous performance test (CPT). With the placebo nicotine patch, there was a haloperidol dose-related impairment in delayed matching to sample choice accuracy and an increase in response time on the complex reaction time task. Nicotine caused a dose-related reversal of the haloperidol-induced impairments in memory performance and complex reaction time. In the CPT, nicotine reduced the variability in response that is associated with attentional deficit. These results demonstrate the effects of nicotine in reversing some of the adverse side effects of haloperidol and improving cognitive performance in schizophrenia.

KW - Haloperidol

KW - Memory

KW - Nicotine

KW - Reaction time

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0030297344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030297344&partnerID=8YFLogxK

U2 - 10.1016/S0893-133X(96)00018-8

DO - 10.1016/S0893-133X(96)00018-8

M3 - Article

VL - 15

SP - 429

EP - 436

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 5

ER -